AXLRx Book a call Commission

Twenty minutes with a consultant, before anything is commissioned.Book a scoping call →

Indications

Every indication in the library.

All indications

Oncology · 6 analysesNSCLCUS NSCLC market: where a pre-launch asset differentiates on biomarker strategy and payer access in a field crowded with checkpoint and targeted therapy.US · In-Market Metabolic · 5 analysesMASHUS MASH market: Rezdiffra and Wegovy are both already in-market on accelerated approval, making preferred payer access a year-one retention fight.US · In-Market Rare Disease · 39 analysesPNHPNH market: why the flow-cytometry diagnosis funnel, not prevalence, sizes the market, and how the oral switch converts the anaemic EVH cohort.US · GCC · FR · UK · DE · In-Market Immunology · 4 analysesAtopic DermatitisAtopic dermatitis market: the black-box step edit that locks dupilumab into first line, and the OX40 pipeline that is the credible threat behind it.US · In-Market Metabolic · 6 analysesType 2 DiabetesType 2 diabetes market: how the GLP-1 transition, a cardiovascular outcomes label, and IRA negotiation of SGLT2 inhibitors reset formulary position.US · In-Market Metabolic · 5 analysesObesityObesity market: prior-authorisation thresholds on the commercial side and no Medicare Part D coverage, the access gap that sets the addressable pool.US · In-Market Neurology · 4 analysesAlzheimer's DiseaseAlzheimer's disease market: Part B coverage with mandatory data collection, and why dosing interval rather than the cognitive-slowing delta decides on access.US · In-Market Rare Disease · 24 analysesIgA NephropathyIgA nephropathy market: sizing the biopsy-gated funnel and sequencing four non-interchangeable mechanisms in a launch wave whose order is unsettled.US · GCC · UK · In-Market Rare Disease · 24 analysesHereditary AngioedemaHereditary angioedema market: positioning where six prophylaxis agents cluster on efficacy, and valuing on attacks averted rather than on list price.US · GCC · UK · In-Market Rare Disease · 24 analysesATTR AmyloidosisATTR amyloidosis market: cardiac and neuropathic are two markets in one name, and scan-centre capacity, not biology, sets how fast the funnel fills.US · UK · GCC · In-Market Rare Disease · 24 analysesMyasthenia GravisMyasthenia gravis market: sizing the inadequately-controlled pool a crowded FcRn and complement class competes for, and modelling the switch flows.US · GCC · UK · In-Market Rare Disease · 24 analysesDravet SyndromeDravet syndrome market: every agent adds on to a generic backbone, so sizing runs off the genetic-identification funnel rather than switching share.US · GCC · UK · In-Market Rare Disease · 24 analysesPompe DiseasePompe disease market: positioning a next-generation ERT on segment rather than average patient, and sizing a late-onset pool mistaken for limb-girdle.US · GCC · UK · In-Market Rare Disease · 24 analysesFabry DiseaseFabry disease market: the amenable-mutation split that gates oral therapy, and why cascade screening adds more value than switching a fixed pool.US · GCC · UK · In-Market Rare Disease · 24 analysesSpinal Muscular AtrophySpinal muscular atrophy market: modelling a one-time gene therapy as a depleting pool, and net price under outcomes-based Medicaid annuities.US · UK · GCC · In-Market Rare Disease · 24 analysesSickle Cell DiseaseSickle cell disease market: a Medicaid-dominant payer case, the CMS cell and gene therapy access model, and a severe pool that depletes as it is treated.US · GCC · UK · In-Market Rare Disease · 6 analysesGaucher DiseaseGaucher disease market: a closed prevalent pool where five agents trade share, CYP2D6 gates oral eligibility, and gene therapy threatens lifetime ERT.US · In-Market Rare Disease · 6 analysesCold Agglutinin DiseaseCold agglutinin disease market: defending a single-agent franchise against its own cost-effectiveness case, and separating treatable patients from titres.US · In-Market Oncology · 10 analysesBreast Cancer HR+/HER2-HR+/HER2- breast cancer market: CDK4/6 holds first line, and after progression the market splits by biomarker, with ESR1, PIK3CA and AKT routed apart.US · UK · In-Market Pulmonology · 4 analysesCOPDCOPD market: after the 2024 add-on approvals the contest is which triple-therapy failure phenotype a payer will treat, and the eosinophil gate decides.US · In-Market Immunology · 5 analysesPlaque PsoriasisPlaque psoriasis market: with PASI 90 the shared bar, competition has moved to dosing interval and oral TYK2 while incumbents erode to biosimilars.US · In-Market

Competitive IntelligenceUS
Disease LandscapeUS
Patient Flow ModelUS
Payer & HTAUS
Field-Force StrategyUS
Launch ReadinessUS

Competitive IntelligenceUS
Disease LandscapeUS
Payer & HTAUS
Launch ReadinessUS
Market Sizing ModelUS

Competitive IntelligenceUS GCC FR UK DE
Disease LandscapeUS UK FR GCC DE
Patient Flow ModelUS UK FR GCC DE
Payer & HTAUS FR GCC UK DE
Launch ReadinessUS FR GCC UK DE
KOL MappingUK FR GCC
Pricing Strategy ModelUS DE UK GCC FR
Market Sizing ModelUS FR DE UK GCC
HTA Strategy ModelUK

Competitive IntelligenceUS
Disease LandscapeUS
Payer & HTAUS
Launch ReadinessUS

Competitive IntelligenceUS
Disease LandscapeUS
Payer & HTAUS
Launch ReadinessUS
Pricing Strategy ModelUS
Market Sizing ModelUS

Competitive IntelligenceUS
Disease LandscapeUS
Payer & HTAUS
Launch ReadinessUS
Pricing Strategy ModelUS

Competitive IntelligenceUS
Disease LandscapeUS
Payer & HTAUS
Launch ReadinessUS

Competitive IntelligenceUS GCC UK
Disease LandscapeUS UK GCC
Patient Flow ModelUS GCC UK
Payer & HTAUS UK GCC
Launch ReadinessUS UK GCC
KOL MappingUK GCC
Pricing Strategy ModelUS UK GCC
Market Sizing ModelUS GCC UK
HTA Strategy ModelUK

Competitive IntelligenceUS GCC UK
Disease LandscapeUS UK GCC
Patient Flow ModelUS GCC UK
Payer & HTAUS GCC UK
Launch ReadinessUS UK GCC
KOL MappingGCC UK
Pricing Strategy ModelUS UK GCC
Market Sizing ModelUS UK GCC
HTA Strategy ModelUK

Competitive IntelligenceUS UK GCC
Disease LandscapeUS UK GCC
Patient Flow ModelUS GCC UK
Payer & HTAUS UK GCC
Launch ReadinessUS GCC UK
KOL MappingUK GCC
Pricing Strategy ModelUS UK GCC
Market Sizing ModelUS UK GCC
HTA Strategy ModelUK

Competitive IntelligenceUS GCC UK
Disease LandscapeUS UK GCC
Patient Flow ModelUS GCC UK
Payer & HTAUS GCC UK
Launch ReadinessUS UK GCC
KOL MappingGCC UK
Pricing Strategy ModelUS UK GCC
Market Sizing ModelUS UK GCC
HTA Strategy ModelUK

Competitive IntelligenceUS GCC UK
Disease LandscapeUS GCC UK
Patient Flow ModelUS GCC UK
Payer & HTAUS UK GCC
Launch ReadinessUS UK GCC
KOL MappingGCC UK
Pricing Strategy ModelUS GCC UK
Market Sizing ModelUS GCC UK
HTA Strategy ModelUK

Competitive IntelligenceUS GCC UK
Disease LandscapeUS UK GCC
Patient Flow ModelUS UK GCC
Payer & HTAUS UK GCC
Launch ReadinessUS UK GCC
KOL MappingGCC UK
Pricing Strategy ModelUS UK GCC
Market Sizing ModelUS GCC UK
HTA Strategy ModelUK

Competitive IntelligenceUS GCC UK
Disease LandscapeUS GCC UK
Patient Flow ModelUS UK GCC
Payer & HTAUS GCC UK
Launch ReadinessUS UK GCC
KOL MappingGCC UK
Pricing Strategy ModelUS UK GCC
Market Sizing ModelUS UK GCC
HTA Strategy ModelUK

Competitive IntelligenceUS GCC UK
Disease LandscapeUS UK GCC
Patient Flow ModelUS GCC UK
Payer & HTAUS UK GCC
Launch ReadinessUS GCC UK
KOL MappingUK GCC
Pricing Strategy ModelUS UK GCC
Market Sizing ModelUS UK GCC
HTA Strategy ModelUK

Competitive IntelligenceUS GCC UK
Disease LandscapeUS UK GCC
Patient Flow ModelUS UK GCC
Payer & HTAUS GCC UK
Launch ReadinessUS GCC UK
KOL MappingUK GCC
Pricing Strategy ModelUS UK GCC
Market Sizing ModelUS GCC UK
HTA Strategy ModelUK

Competitive IntelligenceUS
Disease LandscapeUS
Payer & HTAUS
Launch ReadinessUS
Pricing Strategy ModelUS
Market Sizing ModelUS

Competitive IntelligenceUS
Disease LandscapeUS
Payer & HTAUS
Launch ReadinessUS
Pricing Strategy ModelUS
Market Sizing ModelUS

Competitive IntelligenceUS
Disease LandscapeUS
Patient Flow ModelUS
Payer & HTAUS
Launch ReadinessUS
KOL MappingUS UK
Pricing Strategy ModelUS
Market Sizing ModelUS
HTA Strategy ModelUK

Competitive IntelligenceUS
Disease LandscapeUS
Payer & HTAUS
Launch ReadinessUS

Competitive IntelligenceUS
Disease LandscapeUS
Payer & HTAUS
Launch ReadinessUS
Pricing Strategy ModelUS